Clinical trials: Acute Myelogenous Leukemia (AML)
Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia.
- Trial name
- NCT07108010
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Assiut University
Leukemia
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed.
- Trial name
- NCT01692197
- Testing
- E7070, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia
- Trial name
- NCT00671697
- Testing
- Arsenic Trioxide, Decitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Myeloid Leukemia
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial
In this trial the investigators will evaluate the outcomes of 4 pre-defined groups of individuals according to the therapeutic intervention.
- Trial name
- SIRA (NCT02867891)
- Volunteers
- 396 people
- Sponsor
- Robert Zeiser
Acute Myeloid Leukemia in Children
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
- Trial name
- NCT05994690
- Testing
- Standard Intervention Rc, Investigational Intervention Rc, Standard Intervention Ri
- Where
- Netherlands
- Volunteers
- 905 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Acute Myeloid Leukemia
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- NCT04628026
- Testing
- Venetoclax, Standard chemotherapy, Allogeneic stem cell transplantation
- Where
- 91 sites in Austria, Belgium and 6 more
- Volunteers
- 650 people
- Sponsor
- University of Ulm
Leukemia, FLT3-Mutated Acute Myeloid Leukemia
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
The goal of Part 1 of this clinical research study is to learn if ponatinib alone can help to control FLT3-mutated AML or FLT3-mutated high-risk MDS. The safety of this drug will also be studied.
- Conditions
- Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome
- Trial name
- NCT02829840
- Testing
- Ponatinib, 5-azacytidine, Phone Calls
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed).
- Trial name
- NCT04905810
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brian Jonas
Acute Myeloblastic Leukemia
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
Standard chemotherapy is capable of eliminating most leukemic blasts in acute myeloblastic leukemia (AML), while leukemia-initiating cells are not sufficiently eradicated.
- Trial name
- TOR-AML (NCT01611116)
- Testing
- sodium chloride solution 0.9%, temsirolimus
- Where
- 5 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Goethe University
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
The purpose of this study is to confirm the safety and tolerability of oral panobinostat (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients with Myelodysplastic Syndromes (MDS), Chronic…
- Conditions
- Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)
- Trial name
- NCT01613976
- Testing
- Panobinostat
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Neoplasm
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).
- Trial name
- NCT05656248
- Testing
- CPX-351, MHA, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapse Leukemia, Refractory Acute Myeloid Leukemia
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Relapse Leukemia, Refractory Acute Myeloid Leukemia, Conditioning, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06385808
- Testing
- MTBF regimen
- Volunteers
- 37 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Acute Myeloid Leukemia
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
This is a phase 1, dose escalation study of Plerixafor in combination with granulocyte-colony stimulating factor , Daunorubicin and Cytarabine in adults patients with relapsed acute myeloid leukemia .
- Trial name
- PRIMAL (NCT01455025)
- Testing
- Plerixafor granulocyte-colony stimulating factor
- Where
- France
- Volunteers
- 11 people
- Sponsor
- French Innovative Leukemia Organisation
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving treosulfan together with fludarabine phosphate and total-body irradiation followed by donor stem cell transplant works in treating patients with high-risk acute myeloid leukemia…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00860574
- Testing
- treosulfan, fludarabine phosphate, total-body irradiation
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML)
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC
The goal of this non-interventional study is to evaluate quality of life (QoL) in adult patients with newly diagnosed IDH1 R132-mutated AML who are not eligible to receive standard induction chemotherapy and who are treated with…
- Trial name
- CONFIDHENCE (NCT06181734)
- Testing
- Ivosidenib
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- iOMEDICO AG
Acute Myeloid Leukemia
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia.
- Trial name
- KARMA (NCT05503134)
- Testing
- Universal Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nationwide Children's Hospital
AML
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
The aim of this protocol is to investigate a novel form of immune therapy for patients with acute myelogenous leukemia (AML) who are in remission (CR) but who are at high risk for relapse.
- Trial name
- AMLCTL (NCT00808080)
- Testing
- AMLCTL
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Thomas A. Lane, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.